AF
AXDX

Amalgamated Financial’s Accelerate Diagnostics AXDX Stock Holding History

Amalgamated Financial’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$8K Buy
+537
New +$15.3K ﹤0.01% 2921

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Amalgamated Financial's AXDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Accelerate Diagnostics (AXDX) in Q1 2022: 537 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #2921 among its holdings.

106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

  • Amalgamated Financial held 537 shares of Accelerate Diagnostics worth $8K as of Q1 2022.
  • Accelerate Diagnostics was a new Amalgamated Financial position in Q1 2022.
  • Accelerate Diagnostics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2921 holding.
  • 106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.